Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Habermehl, Daniel ^a,c   Kessel, Kerstin ^a   Welzel, Thomas ^a   Hof, Holger ^a   Abdollahi, Amir ^a   Bergmann, Frank ^b   Rieken, Stefan ^a   Weitz, Jürgen ^a   Werner, Jens ^a   Schirmacher, Peter ^b   Büchler, Markus W ^a   Debus, Jürgen ^a   Combs, Stephanie E ^a  

^a Department of Radiation Oncology ^*  (Germany)

^b Institute of Pathology   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PERITONEUM METASTASIS; POST TREATMENT SURVIVAL; RADIATION DOSE FRACTIONATION; ADJUVANT THERAPY; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS;

EID: 84857683649     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-28     Document Type: Article

References (38)

1. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995, 82:111-115. 10.1002/bjs.1800820137, 7881926.
2. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999, 189:1-7. 10.1016/S1072-7515(99)00075-7, 10401733.
3. Dunst J, Debus J, Rudat V, et al. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol 2008, 184:450-456. 10.1007/s00066-008-1751-4, 19016023.
4. Eich HT, Stepien A, Zimmermann C, et al. Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer: prognostic significance of tumor regression. Strahlenther Onkol 2011, 187:225-230. 10.1007/s00066-011-2113-1, 21424305.
5. Leibl BJ, Vitz S, Schafer W. Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery: early results and toxicity. Strahlenther Onkol 2011, 187:231-237. 10.1007/s00066-011-2171-4, 21437768.
6. Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004, 198:722-731. 10.1016/j.jamcollsurg.2004.01.008, 15110805.
7. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. clinicopathologic analysis of 5-year survivors. Ann Surg 1996, 223:273-279. 10.1097/00000658-199603000-00007, 1235115, 8604907.
8. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000, 4:567-579. 10.1016/S1091-255X(00)80105-5, 11307091.
9. Sperti C, Pasquali C, Piccoli A, et al. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996, 83:625-631. 10.1002/bjs.1800830512, 8689203.
10. Yeo CJ, Sohn TA, Cameron JL, et al. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998, 227:821-831. 10.1097/00000658-199806000-00005, 1191384, 9637545.
11. Adler G, Seufferlein T, Bischoff SC, et al. S3-Guidelines "Exocrine pancreatic cancer" 2007. Z Gastroenterol 2007, 45:487-523. 10.1055/s-2007-963224, 17607616.
12. Butturini G, Pisano M, Scarpa A, et al. Aggressive approach to acinar cell carcinoma of the pancreas: a single-institution experience and a literature review. Langenbecks Arch Surg 2011, 396:363-369. 10.1007/s00423-010-0706-2, 20803029.
13. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740. 10.1056/NEJMoa040694, 15496622.
14. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-2317. 10.1200/JCO.2005.00.034, 15800321.
15. Stoeltzing O, Loss M, Huber E, et al. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 2010, 395:185-192. 10.1007/s00423-009-0520-x, 19506898.
16. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the european organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1997, 15:2040-2049.
17. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349:2091-2098. 10.1056/NEJMoa031317, 14645636.
18. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7:e1000267. 10.1371/journal.pmed.1000267, 2857873, 20422030.
19. Morganti AG, Massaccesi M, La Torre G, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010, 17:194-205. 10.1245/s10434-009-0762-4, 19856029.
20. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995, 22:3-10.
21. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997, 24:S7-24-S27-28.
22. Buchler MW, Wagner M, Schmied BM, et al. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg 2003, 138:1310-1314. discussion 1315, 10.1001/archsurg.138.12.1310, 14662530.
23. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet 2004, 363:1049-1057. 10.1016/S0140-6736(04)15841-8, 3062508, 15051286.
24. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006, 244:10-15. 10.1097/01.sla.0000217673.04165.ea, 1570590, 16794383.
25. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011, 378:607-620. 10.1016/S0140-6736(10)62307-0, 21620466.
26. Tinkl D, Grabenbauer GG, Golcher H, et al. Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol 2009, 185:557-566. 10.1007/s00066-009-1977-9, 19756421.
27. Tempero M, Arnoletti JP, Ben-Josef E, et al. Pancreatic adenocarcinoma. clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007, 5:998-1033.
28. Bilimoria KY, Bentrem DJ, Feinglass JM, et al. Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. J Clin Oncol 2008, 26:4626-4633. 10.1200/JCO.2007.15.6356, 18574159.
29. Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg 2007, 246:173-180. 10.1097/SLA.0b013e3180691579, 1933550, 17667493.
30. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer 2007, 110:1227-1234. 10.1002/cncr.22916, 17654662.
31. Bilimoria KY, Talamonti MS, Sener SF, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008, 207:510-519. 10.1016/j.jamcollsurg.2008.04.033, 18926452.
32. Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 2008, 247:490-500. 10.1097/SLA.0b013e31815b9cae, 18376195.
33. Gordon TA, Burleyson GP, Tielsch JM, et al. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg 1995, 221:43-49. 10.1097/00000658-199501000-00005, 1234493, 7826160.
34. Imperato PJ, Nenner RP, Starr HA, et al. The effects of regionalization on clinical outcomes for a high risk surgical procedure: a study of the Whipple procedure in New York State. Am J Med Qual 1996, 11:193-197. 10.1177/0885713X9601100407, 8972936.
35. Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998, 228:429-438. 10.1097/00000658-199809000-00016, 1191507, 9742926.
36. Brunner TB, Scott-Brown M. The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 2010, 5:64. 10.1186/1748-717X-5-64, 2911464, 20615227.
37. Gaedcke J, Gunawan B, Grade M, et al. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg 2010, 395:451-458. 10.1007/s00423-009-0494-8, 2848727, 19418067.
38. Van den Broeck A, Sergeant G, Ectors N, et al. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2009, 35:600-604. 10.1016/j.ejso.2008.12.006, 19131205.